Pliant Therapeutics Inc. (PLRX)
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration
Pliant Therapeutics trades at a deep discount to net cash after Bexotegrast's Phase 3 failure, with a $70M market cap versus $186M cash. Activist Kevin Tang holds 9.6%; given the 85%+ institutional base, the March 2026 poison pill expiration signals a potential liquidation or premium buyout. PLRX's cash burn has been slashed, extending runway to 2028, but continued independent operation is untenable; forced liquidation or cash privatization is highly likely in my opinion.
PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know
PLIANT THERAPT (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pliant Therapeutics: An Activist On Deck
Pliant Therapeutics suffered a major setback with its lead drug candidate, causing its stock to plummet well below its cash value. Activist investor Kevin Tang has acquired a significant stake in PLRX, aiming to capitalize on the company's large cash reserves. Tang's history of acquiring biotechs at a discount suggests a potential profitable takeover of PLRX, despite management's defensive "poison pill" strategy.
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
Pliant stock crashes 89% in three months following setbacks in the mid-stage study of its lead candidate, bexotegrast, for idiopathic pulmonary fibrosis.
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
On Monday, Pliant Therapeutics Inc. PLRX announced that it would discontinue the BEACON-IPF Phase 2b trial, which evaluated bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).
All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy
PLIANT THERAPT (PLRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues
Pliant Therapeutics, Inc. PLRX stock is trading lower on Monday.
